Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2026)

Acadia Pharmaceuticals' Receivables history runs 11 years deep, the most recent figure standing at $148.4 million for Q1 2026.

• In Q1 2026, Receivables rose 30.49% year-over-year to $148.4 million; the TTM figure through Mar 2026 stood at $148.4 million (up 30.49% YoY), while the FY2025 annual figure was $148.2 million, up 41.58% from the prior year.
• Receivables was $148.4 million for Q1 2026 at Acadia Pharmaceuticals, roughly flat from $148.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $148.4 million in Q1 2026 to a low of $56.1 million in Q3 2022.
• Historically, Receivables has averaged $99.9 million across 5 years, with a median of $102.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Receivables retreated 8.97% in 2022, then soared 68.4% in 2023.
• A 5-year view of Receivables shows it stood at $63.1 million in 2022, then jumped by 62.25% to $102.4 million in 2023, then increased by 2.29% to $104.7 million in 2024, then surged by 41.58% to $148.2 million in 2025, then advanced by 0.1% to $148.4 million in 2026.
• The last three Receivables figures came in at $148.4 million (Q1 2026), $148.2 million (Q4 2025), and $139.4 million (Q3 2025), per Business Quant data.